Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02749799 · ClinicalTrials.gov registry record · Phase 4
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
A Phase 4 study of Plaque Psoriasis, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT02749799: Completed Phase 4 study of Plaque Psoriasis, sponsored by Primus Pharmaceuticals.
NCT02749799 is a Phase 4 study of Plaque Psoriasis that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 45 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02749799, a Phase 4 study of Plaque Psoriasis, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
Primary Outcome
The mean change in the IGA score from baseline to Day 14 was assessed. IGA score is a static assessment of disease severity and is based on overall severity of signs at each visit. It's a 4-point scale where '0' is absent disease and '4' is 'Severe/Very Severe' disease. A lower score at the end of the study compared to baseline (negative change), indicates an improvement in the disease condition.
Conditions Studied
Interventions
- DRUG DFD-01 (betamethasone dipropionate) Spray, 0.05%
Study Locations (4)
Illinois
- Site Four - Arlington Heights
Indiana
- Site Two - New Albany
Kentucky
- Site One - Louisville
Nevada
- Site Three - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
What the finished NCT02749799 record still lists
NCT02749799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which DFD-01 (betamethasone dipropionate) Spray, 0.05% is the first listed.
NCT02749799 reports a single indexed study location in Illinois, Indiana, Kentucky.
Frequently Asked Questions
What is clinical trial NCT02749799 about?
NCT02749799 is a clinical study titled "Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis". The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
What is the current status of trial NCT02749799?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2016-02. Estimated completion is 2016-08.
What conditions does trial NCT02749799 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT02749799?
The interventions under investigation include: DFD-01 (betamethasone dipropionate) Spray, 0.05% (DRUG).
Who is sponsoring clinical trial NCT02749799?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02749799 being conducted?
This trial has 4 study locations across Illinois, Indiana, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02749799's enrollment target sits among peer trials
45 38th of 45 higher than 8 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Guselkumab Immunogenetics
RECRUITING · Phase 4
-
Bimekizumab in Plaque Psoriasis
RECRUITING · Phase 4
-
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
COMPLETED · Phase 4
-
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
COMPLETED · Phase 4
-
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
COMPLETED · Phase 4
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia